Cancer Therapies Pipeline | Takeda Oncology
Our Pipeline
Our Pipeline
Our research and development efforts focus on advancing medicines for hematologic, thoracic and gastrointestinal cancers by leveraging modalities best suited to make a difference in the treatment of these diseases. Our core modalities include antibody-drug conjugates (ADCs), complex biologics, small molecules and gamma delta T cell therapies.
These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.
| Investigational therapy | Modality | Investigational indication | Phase | ||
Brentuximab vedotin* | |||||
ADC | Newly diagnosed Hodgkin lymphoma (EU) | Filed | |||
Elritercept (TAK-226)† | |||||
Complex biologic | Second-line anemia-associated myelodysplastic syndromes | Phase 3 | |||
Complex biologic | Anemia-associated myelofibrosis | Phase 2 | |||
Mirvetuximab soravtansine-gynx (TAK-853) | |||||
ADC | Folate receptor alpha (FRα)-positive platinum-sensitive ovarian cancer (JP) | Phase 3 | |||
ADC | Folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (JP) | Phase 1/2 | |||
Rusfertide (TAK-121) | |||||
Small molecule | Polycythemia vera (USA) | Phase 3 | |||
TAK-012 | |||||
Gamma delta T cell therapy | Acute myeloid leukemia | Phase 1/2a |
*Marketed products have received approval in one or more jurisdictions.
†Treatments have one or more clinical trials in active recruitment.
All programs have global development rights unless otherwise noted.
GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets.
Investors
To learn more about Oncology-specific Investor events and information, visit the Takeda Oncology Investor Relations page
